Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 11/20 | 0.72 |
| ▸ | KDR | P35968 | 6/20 | 0.72 |
| ▸ | LCK | P06239 | 2/20 | 0.71 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | FES | P07332 | 1/20 | 0.71 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | IGF1R | P08069 | 1/20 | 0.71 |
| ▸ | MET | P08581 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | FGR | P09769 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.71 |
| ▸ | CSK | P41240 | 1/20 | 0.71 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12543704 | 0.85 | TEK (0.72) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265313 | 0.84 | TEK (0.78) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265824 | 0.83 | TEK (1.00) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1264383 | 0.83 | TEK (1.00) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265011 | 0.80 | TEK (0.71) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265034 | 0.79 | TEK (0.92) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265456 | 0.79 | TEK (0.70) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265791 | 0.78 | TEK (0.90) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1264710 | 0.78 | TEK (0.90) | TEKKDRLCKNTRK1EGFR | |
| SCHEMBL1265430 | 0.78 | TEK (0.90) | TEKKDRLCKNTRK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | claimed |
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | TEK 11/4885KDR 4/4885LCK 409/4885 |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | TIE1, AURKB, TEK | TEK 3/4885KDR 5/4885LCK 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.